Liver Transplant for Metastatic Neuroendocrine Tumors: A Single-Center Experience in Hungary

Korda, Dávid; Doros, Attila; Piros, László; Gerlei, Zsuzsanna; Haboub-Sandil, Anita; Mándli, Tamás; Fazakas, János; Deák, Ákos P.; Máthé, Z.

doi:10.1016/j.transproceed.2019.04.010

Cited by 13 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most recent publications (Table 6) confirm the commonly used selection criteria with a reported 5-year OS of 83 [63], 71 [62], and 64.9% [61]. Both pancreatic NELM and NELM with a Ki67 > 5% [62] and patients ≤45 years of age or waiting for LT <6 months have a higher RR [61]. Further G1 and a low number or small size (<3 cm) of NELM are beneficial for a 5-year survival of 92, 100, and 100%, respectively [63].…”

Section: Discussion/conclusionmentioning

confidence: 73%

“…The estimated 1- and 5-year RFS rates were 80 and 43%, respectively. Every patient whose primary tumor was of pancreatic origin or those recipients who had Ki67 index values in the explanted liver >5% have developed recurrent disease [62]. Ruzzenente et al [63] analyzed a multi-institutional cohort of 28 patients including status post-resection of portal system-drained NET, patients with stable disease or response to therapies for ≥6 months, <50% tumor mass of total liver volume, low-grade NET, and age ≤60 years.…”

Section: Resultsmentioning

confidence: 99%

“…Patients with NELM should therefore be introduced to a highly specialized transplant center and be evaluated for LT [86]. Most recent publications (Table 6) confirm the commonly used selection criteria with a reported 5-year OS of 83 [63], 71 [62], and 64.9% [61]. Both pancreatic NELM and NELM with a Ki67 > 5% [62] and patients ≤45 years of age or waiting for LT <6 months have a higher RR [61].…”

Section: Discussion/conclusionmentioning

confidence: 99%

See 2 more Smart Citations

Liver Transplantation in Malignancies: A Comprehensive and Systematic Review on Oncological Outcome

et al. 2021

View full text Add to dashboard Cite

Introduction: Liver transplantation (LT) is today’s standard treatment for both end-stage liver disease and tumors; however, suitable grafts for LT are a scarce resource and outcome after LT is highly dependent on its underlying indication. Thus, patients must be carefully selected to optimize the number of life years gained per graft. This comprehensive and systematic review critically reflects the most recently published oncological outcome data after LT in malignancies based on the preoperative radiological findings. Methods: A systematic literature search was conducted to detect preferentially most recent high-volume series or large database analysis on oncological outcomes after LT for both primary liver cancer and liver metastases between January 1, 2019, and November 14, 2020. A comprehensive review on the radiological assessment of the reviewed liver malignancies is included and its preoperative value for an outcome-driven indication reflected. Results: Twenty most recent high-volume or relevant studies including a total number of 2,521 patients were identified including 4, 4, 4, 4, 3, and 1 publications on oncological outcome after LT for hepatocellular carcinoma, cholangiocellular carcinoma, hepatic epitheloid hemangioendothelioma, hepatoblastoma, and both metastatic neuroendocrine tumors and colorectal cancer, respectively. The overall survival is comparable to patients without tumors if patients with malignancies are well selected for LT; however, this is highly dependent on tumor entity, tumor stage, and both neoadjuvant and concomitant treatment. Discussion/Conclusion: LT is a promising option for better survival in patients with malignant liver tumors in selected patients; however, the indication must be critically discussed prior to LT in every single case in the context of organ shortage.

show abstract

Section: Discussion/conclusionmentioning

confidence: 73%

Section: Resultsmentioning

confidence: 99%

Section: Discussion/conclusionmentioning

confidence: 99%

See 1 more Smart Citation

Liver Transplantation in Malignancies: A Comprehensive and Systematic Review on Oncological Outcome

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Con frecuencia es necesaria la cirugía citorreductora y quimioterapia, para prolongar la supervivencia. La octreotida es útil en las pacientes con síntomas del síndrome carcinoide para aliviar la sintomatología y prevención de la progresión de la cardiopatía (14) . El tratamiento perioperatorio debe incluir infusión intravenosa con octreotida para reducir el riesgo de crisis carcinoide.…”

Section: Discussionunclassified

Tumor carcinoide primario de ovario. Reporte de caso

Valencia-West¹,

Gericke-Brumm²

2020

Rev peru ginecol obstet.

View full text Add to dashboard Cite

Los tumores neuroendocrinos primarios del ovario son raros y consisten en un grupo de neoplasias heterogéneas que expresan marcadores inmunohistoquímicos similares. Los tumores carcinoides son las neoplasias neuroendocrinas más comunes, la mayoría surgen en el tracto gastrointestinal y broncopulmonar. Los tumores carcinoides primarios del ovario son entidades raras que representan aproximadamente 0,3% de todos los tumores carcinoides y menos del 0,1% de todas las neoplasias ováricas, con buen pronóstico y generalmente limitados al parénquima ovárico. Estos tumores surgen del sistema de células neuroendocrinas del estroma, epitelio superficial y teratomas ováricos. Las manifestaciones clínicas, en la mayoría de los casos, están asociadas con liberación de sustancias vasoactivas que causan síntomas, como enrojecimiento cutáneo, diarrea y broncoespasmo. Para realizar el diagnóstico es necesario el uso de imágenes radiológicas multimodales y análisis bioquímicos de marcadores tumorales neuroendocrinos. El tratamiento de primera línea es la resección del tumor siempre que sea posible. El pronóstico es generalmente favorable, excepto en algunos casos con metástasis. Se presenta un caso de tumor carcinoide primario de ovario.

show abstract

“…In the more recent prospective SECA-II trial, 15 patients underwent LT for unresectable CRLM. Even if the DFS was the price to pay (i.e., the 1, 2, and 3 years DFS were 53%, 44%, and 35%, respectively), the OS achieved was of paramount importance (i.e., the 1, 3, and 5 years OS were 100%, 83%, and 83%, respectively) [34]. All the patients received pre-transplant systemic chemotherapy and at least 10% response was necessary in order to be included in the SECA-II protocol.…”

Section: Liver Transplantation: Outcomesmentioning

confidence: 99%

The Revolution in Indication for Liver Transplantation: Will Liver Metastatic Disease Overcome the End-Stage Liver Disease in the Next Future?

et al. 2020

View full text Add to dashboard Cite

Indications for liver transplantation (LT) have constantly been evolving during the last few decades due to a better understanding of liver diseases and innovative therapies. Likewise, also the underlying causes of liver disease have changed. In the setting of transplant oncology, recent developments have pushed the boundaries of oncological indications for LT outside hepatocellular carcinoma (HCC), especially for secondary liver tumors, such as neuroendocrine and colorectal cancer. In the next years, as more evidence emerges, LT could become the standard treatment for well-selected metastatic liver tumors. In this manuscript, we review and summarize the available evidence for LT in liver tumors beyond HCC with a focus on metastatic liver malignancies, highlighting the importance of these new concepts for future implications.

show abstract

Liver Transplant for Metastatic Neuroendocrine Tumors: A Single-Center Experience in Hungary

Cited by 13 publications

References 14 publications

Liver Transplantation in Malignancies: A Comprehensive and Systematic Review on Oncological Outcome

Liver Transplantation in Malignancies: A Comprehensive and Systematic Review on Oncological Outcome

Tumor carcinoide primario de ovario. Reporte de caso

The Revolution in Indication for Liver Transplantation: Will Liver Metastatic Disease Overcome the End-Stage Liver Disease in the Next Future?

Contact Info

Product

Resources

About